TY - CHAP M1 - Book, Section TI - Allergic Bronchopulmonary Aspergillosis (Mycosis) and Severe Asthma with Fungal Sensitivity A1 - Chupp, Geoffrey L. A2 - Grippi, Michael A. A2 - Antin-Ozerkis, Danielle E. A2 - Dela Cruz, Charles S. A2 - Kotloff, Robert M. A2 - Kotton, Camille Nelson A2 - Pack, Allan I. Y1 - 2023 N1 - T2 - Fishman’s Pulmonary Diseases and Disorders, 6e AB - Allergic bronchopulmonary aspergillosis (ABPA) is an idiopathic inflammatory disease of the lung, characterized by an allergic inflammatory response to colonization of the airways by Aspergillus fumigatus or other fungi. The entity was first described in 1952 by Hinson et al., and then again in 1967, when Scadding recognized an association between the disease and proximal bronchiectasis in areas previously affected by infiltrates (predominantly in the upper lobes).1,2 The first adult case of ABPA was reported in the United States in 1968.3 Although most cases entail hypersensitivity to Aspergillus spp. (i.e., A. fumigatus or niger), the finding of a virtually identical clinical syndrome associated with immune sensitivity to Candida albicans (most commonly), Helminthosporium, Alternaria, Curvularia lunata, Drechslera hawaiiensis, Stemphylium languinosum, Saccharomyces cerevisiae, or Pseudallescheria boydii has led some to use the term allergic bronchopulmonary mycosis to describe the syndrome.4 However, since the predominant causative organism is A. fumigatus (and the commercially available laboratory testing is for this organism and A. niger), ABPA is primarily designated as the diagnosis. In addition, a recently recognized entity appears to be on the continuum between fungal allergy, at one end, and ABPA at the other: severe asthma with fungal sensitivity (SAFS).5 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1194951033 ER -